Evidence map›Paper›PMID 32019921›Full record

ArticleNature communications2020

Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles.

Hiroki Tsujinaka, Jie Fu, Jikui Shen, Yun Yu, Zibran Hafiz, Joshua Kays, David McKenzie, Delia Cardona, David Culp, Ward Peterson and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Ranibizumab port delivery system for neovascular age-related macular degeneration: Current evidence and surgical considerations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
  4. Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  5. Review
  6. Article
  7. Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Next generation therapeutics for retinal neurodegenerative diseases.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  17. Article
  18. Review
  19. Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Hiroki Tsujinaka *The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jie Fu *The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jikui Shen *The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yun Yu *Graybug Vision, Inc., Redwood City, CA, USA.
Zibran HafizThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Joshua KaysGraybug Vision, Inc., Redwood City, CA, USA.
David McKenzieGraybug Vision, Inc., Redwood City, CA, USA.ORCID http://orcid.org/0000-0002-5533-8370
Delia CardonaGraybug Vision, Inc., Redwood City, CA, USA.
David CulpPowered Research, LLC, Research Triangle Park, Triangle Park, NC, USA.
Ward PetersonGraybug Vision, Inc., Redwood City, CA, USA.
Brian C GilgerPowered Research, LLC, Research Triangle Park, Triangle Park, NC, USA.
Christopher S CreanGraybug Vision, Inc., Redwood City, CA, USA.
Jin-Zhong ZhangGraybug Vision, Inc., Redwood City, CA, USA.
Yogita KananThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6814-3484
Weiling YuGraybug Vision, Inc., Redwood City, CA, USA.
Jeffrey L ClelandGraybug Vision, Inc., Redwood City, CA, USA.
Ming YangGraybug Vision, Inc., Redwood City, CA, USA. myang@graybug.com.
Justin HanesThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. hanes@jhmi.edu.
Peter A CampochiaroThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. pcampo@jhmi.edu.ORCID http://orcid.org/0000-0003-2531-8229
Graybug Vision (United States) · USJohns Hopkins University · USTriangle · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neovascular age-related macular degeneration and diabetic retinopathy are prevalent causes of vision loss requiring frequent intravitreous injections of VEGF-neutralizing proteins, and under-treatment is common and problematic. Here we report incorporation of sunitinib, a tyrosine kinase inhibitor that blocks VEGF receptors, into a non-inflammatory biodegradable polymer to generate sunitinib microparticles specially formulated to self-aggregate into a depot. A single intravitreous injection of sunitinib microparticles potently suppresses choroidal neovascularization in mice for six months and in another model, blocks VEGF-induced leukostasis and retinal nonperfusion, which are associated with diabetic retinopathy progression. After intravitreous injection in rabbits, sunitinib microparticles self-aggregate into a depot that remains localized and maintains therapeutic levels of sunitinib in retinal pigmented epithelium/choroid and retina for more than six months. There is no intraocular inflammation or retinal toxicity. Intravitreous injection of sunitinib microparticles provides a promising approach to achieve sustained suppression of VEGF signaling and improve outcomes in patients with retinal vascular diseases.

Indexed as

AnimalsChoroidal NeovascularizationFemaleHumansMaleMiceMice, Inbred C57BLRabbitsReceptors, Vascular Endothelial Growth FactorRetinal DiseasesSunitinibSwineSwine, MiniatureVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorSunitinibVascular Endothelial Growth Factor A

Identifiers

PMID32019921
PMCPMC7000758
OpenAlexW3005169765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.